Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 6946 AL 6960

The pleiotropic neuroprotective effects of resveratrol in cognitive decline and Alzheimer's disease pathology: From antioxidant to epigenetic therapy

Griñán-Ferré C, Bellver-Sanchis A, Izquierdo V, Corpas R, Roig-Soriano J, Chillón M, Andres-Lacueva C, Somogyvári M, Sőti C, Sanfeliu C, Pallàs M.

Ageing Res Rev. 2021 May;67:101271. doi: 10.1016/j.arr.2021.101271. Epub 2021 Feb 8.

Targeting impaired nutrient sensing with repurposed therapeutics to prevent or treat age-related cognitive decline and dementia: A systematic review

Kioussis B, Tuttle CSL, Heard DS, Kennedy BK, Lautenschlager NT, Maier AB.

Ageing Res Rev. 2021 May;67:101302. doi: 10.1016/j.arr.2021.101302. Epub 2021 Feb 17.

Mural Cells: Potential Therapeutic Targets to Bridge Cardiovascular Disease and Neurodegeneration

Lin A, Peiris NJ, Dhaliwal H, Hakim M, Li W, Ganesh S, Ramaswamy Y, Patel S, Misra A.

Cells. 2021 Mar 8;10(3):593. doi: 10.3390/cells10030593.

Cyclin-Dependent Kinases (CDK) and Their Role in Diseases Development-Review

Łukasik P, Załuski M, Gutowska I.

Int J Mol Sci. 2021 Mar 13;22(6):2935. doi: 10.3390/ijms22062935.

Potential of Medicinal Plants as Neuroprotective and Therapeutic Properties Against Amyloid-β-Related Toxicity, and Glutamate-Induced Excitotoxicity in Human Neural Cells

Lobine D, Sadeer N, Jugreet S, Suroowan S, Keenoo BS, Imran M, Venugopala KN, Ibrahim FM, Zengin G, Mahomoodally MF.

Curr Neuropharmacol. 2021;19(9):1416-1441. doi: 10.2174/1570159X19666210412095251.

Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders

Hölscher C.

Br J Pharmacol. 2022 Feb;179(4):695-714. doi: 10.1111/bph.15508. Epub 2021 May 29.

Chronic Neurological Disorders: Genetic and Epigenetic Markers for Monitoring of Pharmacotherapy

Sarangi SC, Sopory P, Reeta KH.

Neurol India. 2021 Mar-Apr;69(2):252-259. doi: 10.4103/0028-3886.314522.

Recent Developments in New Therapeutic Agents against Alzheimer and Parkinson Diseases: In-Silico Approaches

Cruz-Vicente P, Passarinha LA, Silvestre S, Gallardo E.

Molecules. 2021 Apr 11;26(8):2193. doi: 10.3390/molecules26082193.

Emerging Application of Nanorobotics and Artificial Intelligence To Cross the BBB: Advances in Design, Controlled Maneuvering, and Targeting of the Barriers

Singh AV, Chandrasekar V, Janapareddy P, Mathews DE, Laux P, Luch A, Yang Y, Garcia-Canibano B, Balakrishnan S, Abinahed J, Al Ansari A, Dakua SP.

ACS Chem Neurosci. 2021 Jun 2;12(11):1835-1853. doi: 10.1021/acschemneuro.1c00087. Epub 2021 May 19.

Tailoring of P-glycoprotein for effective transportation of actives across blood-brain-barrier

Pathan N, Shende P.

J Control Release. 2021 Jul 10;335:398-407. doi: 10.1016/j.jconrel.2021.05.046. Epub 2021 Jun 2.

Multitarget therapeutic approaches for Alzheimer's and Parkinson's diseases: an opportunity or an illusion?

Matos MJ.

Future Med Chem. 2021 Aug;13(15):1301-1309. doi: 10.4155/fmc-2021-0119. Epub 2021 Jun 17.

Mitochondrial nanomedicine: Subcellular organelle-specific delivery of molecular medicines

Milane L, Dolare S, Jahan T, Amiji M.

Nanomedicine. 2021 Oct;37:102422. doi: 10.1016/j.nano.2021.102422. Epub 2021 Jun 25.

Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview

Lindberg MF, Meijer L.

Int J Mol Sci. 2021 Jun 3;22(11):6047. doi: 10.3390/ijms22116047.

Therapeutic potential of catalpol and geniposide in Alzheimer's and Parkinson's diseases: A snapshot of their underlying mechanisms

Zhang X, Liu K, Shi M, Xie L, Deng M, Chen H, Li X.

Brain Res Bull. 2021 Sep;174:281-295. doi: 10.1016/j.brainresbull.2021.06.020. Epub 2021 Jul 1.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias